Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods

ABSTRACT This study was designed to examine the effects of antifungal carryover, agitation, and starting inoculum on the results of time-kill tests conducted with various Candida species. Two isolates each of Candida albicans, Candida tropicalis, and Candida glabrata were utilized. Test antifungal agents included fluconazole, amphotericin B, and LY303366. Time-kill tests were conducted in RPMI 1640 medium buffered with morpholinepropanesulfonic acid (MOPS) to a pH of 7.0 and incubated at 35°C. Prior to testing, the existence of antifungal carryover was evaluated at antifungal concentrations ranging from 1× to 16× MIC by four plating methods: direct plating of 10, 30, and 100 μl of test suspension and filtration of 30 μl of test suspension through a 0.45-μm-pore-size filter. Time-kill curves were performed with each isolate at drug concentrations equal to 2× MIC, using a starting inoculum of approximately 105 CFU/ml, and incubated with or without agitation. Last, inoculum experiments were conducted over three ranges of starting inocula: 5 × 102 to 1 × 104, >1 × 104 to 1 × 106, and >1 × 106 to 1 × 108 CFU/ml. Significant antifungal carryover (>25% reduction in CFU/milliliter from the control value) was observed with amphotericin B and fluconazole; however, carryover was eliminated with filtration. Agitation did not appreciably affect results. The starting inoculum did not significantly affect the activity of fluconazole or amphotericin B; however, the activity of LY303366 may be influenced by the starting inoculum. Before antifungal time-kill curve methods are routinely employed by investigators, methodology should be scrutinized and standardized procedures should be developed.

[1]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[2]  R. Pearson,et al.  Method of reliable determination of minimal lethal antibiotic concentrations , 1980, Antimicrobial Agents and Chemotherapy.

[3]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[4]  M. Klepser,et al.  Growth medium effect on the antifungal activity of LY 303366. , 1997, Diagnostic microbiology and infectious disease.

[5]  M. Klepser,et al.  Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366 , 1998, Antimicrobial Agents and Chemotherapy.

[6]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Klepser,et al.  Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. , 1996, Diagnostic microbiology and infectious disease.

[8]  M. Pfaller,et al.  In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents , 1997, Antimicrobial agents and chemotherapy.

[9]  Russell E. Lewis,et al.  Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination againstCandida albicans by Using a Dynamic In Vitro Mycotic Infection Model , 1998, Antimicrobial Agents and Chemotherapy.

[10]  M. Klepser,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. , 1998, The Journal of antimicrobial chemotherapy.